ArticleTherapeutic advances in medical oncology2025
Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- Article
- [Variables associated with severe cytopenia in adult chronic phase chronic myeloid leukemia patients receiving initial tyrosine kinase inhibitors].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.Drug design, development and therapy · 2026Article
- First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience.Mediterranean journal of hematology and infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Flumatinib is a novel second-generation tyrosine kinase inhibitor (2G-TKI), which was approved in November 2019 in China. A previous phase III study evaluated the efficacy and safety of flumatinib as a first-line therapy for patients with chronic phase chronic myeloid leukemia (CML-CP). However, randomized trials comparing flumatinib with other 2G-TKIs remain lacking. Objectives: To assess the efficacy and safety of flumatinib versus nilotinib as a first-line treatment for CML-CP. Design: A multicenter retrospective study. Methods: We retrospectively analyzed 101 and 64 patients treated with flumatinib and nilotinib during the same period, respectively. Results: Patients in the flumatinib group were significantly older than patients in the nilotinib group (median age, 44 vs 37 years; Conclusion: Flumatinib is a suitable alternative as a first-line treatment for patients with CML-CP to achieve a fast MMR with better tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.